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ABSTRACT
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that establishes a life-
long latent infection of B cells. It is usually asymptomatic in healthy individuals;
however, individuals with compromised immunity often develop EBV-induced
lymphoma. EBV also encodes potential oncogenes that can contribute to
tumorigenesis. Therefore , vaccine and immunotherapeutic strategies targeting
EBV are desirable. Recent studies have shown that infusion of EBV-specific
CD8+ T cells can elicit remission of lymphomas arising after administration of
immunosuppressive drugs during transplantation , suggesting an important role
for T cells in the prevention of EBV-induced malignancy. A better understanding
of the cellular immune components involved in the control of EBV will aid in the
development of methods to prevent infection and/or treat EBV-associated
disease.
While EBV infection is usually acquired asymptomatically during
childhood , primary infection of adolescents and young adults can result in an
illness termed acute infectious mononucleosis (AIM). Because of the
characteristic symptoms of the illness, individuals with AIM can be readily
identified and diagnosed with acute EBV infection. Thus , primary CD4+ and
CD8+ T cell responses against the virus can be evaluated. It has been previously
found that there is a marked expansion of lytic EBV protein-specific CD8+ T cells
early during AIM , with delayed detection of lower frequencies of latent EBV
viii
protein-specific CD8+ T cells. The magnitude and specificity of CD4+ T cell
responses during AIM has been less well characterized.
This thesis dissertation presents data from both functional assays and
direct staining experiments documenting the timing, magnitude, and antigen-
specificity of CD4+ T cells over the course of primary EBV infection. Lytic and
latent protein-specific CD4+ T cells were readily detected by intracellular IFN-
production at presentation with AIM and declined rapidly thereafter. Blood EBV
load was also quantitated and found to decrease over time following AIM. 
contrast , CD8+ T celllFN-y responses remained high for several weeks following
presentation with AIM.
Direct staining of lytic epitope-specific CD4+ T cells during AIM revealed
high frequencies of virus-specific cells with low proliferative and IFN- producing
potential. Blood EBV load in these patients was persistently high through 6 wk
following AIM. These data suggest a relationship between high EBV load during
acute infection and impaired EBV-specific CD4+ T cell responses , which are
compatible with impaired CD4+ T cell responses reported during high viremia
associated with other viral infections. This may represent a mechanism by which
persistent viruses , such as EBV, are able to establish a life- long infection in their
hosts.
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CHAPTER I
INTRODUCTION
A. Family Herpesviridae
Herpesviridae consists of a group of ubiquitous viruses that infect and
establish lifelong persistence in their hosts. Classification within the family
Herpesviridae is based on the following structural properties: a large , double-
stranded linear DNA genome enclosed within an icosahedral capsid , a lipid
envelope with glycoprotein spikes, and tegument, or space between the
nucleocapsid and the outer lipid membrane. Herpesviruses encode numerous
gene products that have many functions, including gene regulation , viral
replication , and immune modulation. The virus replication cycle results in lysis of
the infected cell. A common characteristic of all herpesviruses is their ability to
establish latency in a specific cell type or subset of cells. During latent infection
the viral genome circularizes and is transcriptionally restricted. Thus
herpesviruses are never cleared , but are carried in their hosts for life. Latency is
clinically asymptomatic; however, viral reactivations can result in various clinical
manifestations.
Herpesviruses are prevalent throughout nature and have been isolated
from most animal species. They are divided into three subfamilies (alpha , beta
and gamma) based mainly on host range and length of reproductive cycle.
Human alphaherpesviruses include herpes simplex-type 1 (HSV-1), which
causes cold sores, herpes simplex-type 2 (HSV-2), or genital herpes, and
varicella/zoster (VZV), which causes chicken pox during primary infection.
Human betaherpesviruses include cytomegalovirus (CMV) and roseola virus
(HHV-7). Members of the human gammaherpesvirus family include Epstein-Barr
(EBV) and Kaposi's sarcoma (KSHV).
B. Epstein-Barr Virus (EB 
1. Brief history and epidemiology
In the mid-1960' , herpesvirus- like particles were visualized by electron
microscopy from Burkitt's lymphoma- derived lymphoid cells (1 , 2). The virus
later named Epstein-Barr virus (EBV), was soon thereafter found in other
lymphoid tumor cells. Because transformed lymphocytes could be isolated from
the blood of acute infectious mononucleosis (AIM) patients (3), oropharyngeal
secretions from AIM patients were tested and found to be able to transform
lymphocytes (4). It was later determined that EBV was indeed the causative
agent of AIM (5 , 6). But surprisingly, it was also found that over 90% of the
general population had been infected with the virus , as evidenced by serum
antibodies reactive with EBV (7).
EBV is mainly transmitted through saliva. Primary EBV infection usually
occurs during childhood and is most often asymptomatic (S). However, when
primary infection is delayed until adolescence or later, which is most common in
the developed Western world , presentation with symptoms of AIM can result (9).
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After resolution of acute infection , the virus persists for life , rarely causing any
clinical consequence to the host. However
, due to its transforming ability in vitro
it is not surprising that EBV has been associated with many malignancies. These
include Burkitt's lymphoma , nasopharyngeal carcinoma , and Hodgkin s disease.
Ongoing cellular immunity is crucial for the control of EBV. Post-transplant
Iymphoproliferative disease (PTLD) often results when immunosuppressive drugs
are administered during transplantation. Additionally, acute EBV infection can
cause a fulminant infectious mononucleosis , resulting in death of individuals with
a genetic defect in SLAM-associated protein (SAP) (10- 12). This gene is carried
on the X chromosome, and thus the disease is known as X- linked
Iymphoproliferative disease (XLP).
2. Viral life cycle
2. 1 Latent infection
The primary target of EBV infection is the B lymphocyte. Viral entry is
mediated by binding of the viral glycoprotein , gp350/220 to its receptor , CD21 , on
the B cell , followed by vesicular internalization of the virus (13 , 14). While the
early events after viral fusion and internalization are not fully understood
circularization of the viral genome into an episome within the nucleus is known to
occur by 16 h after infection (15 , 16). In vitro infection of B cells invariably results
in activation , proliferation , and transformation of the cells into continuously
growing B Iymphoblastoid cell lines (BLCLs). This is the result of a complex viral
- .
gene transcription program that drives B cell activation and proliferation. The key
transcriptional activator for this program is EBNA- , which is upregulated to
consistent levels by 24 to 32 hours post-infection (15).
EBNA-2 transactivates both cellular genes involved in B cell activation as
well as the expression of viral latent genes by transcriptionally transactivating all
of the latent gene promoters. The latent genes expressed by proliferating BLCLs
include 6 nuclear proteins (EBNA-
, - , - , - , -
, and -LP), 3 membrane
proteins (LMP-
, -
, and -2B), and 2 virally encoded RNAs (EBER-1 and -2).
In vitro transformation of B cells requires EBNA-2 and LMP- , but EBNA-
, -
and -3C also playa crucial role in transformation (17). EBNA-1 is required for
maintenance of the episomal viral genome in infected cells.
A key difference between in vitro and in vivo EBV infection of B cells is
that EBV rarely causes outgrowth of transformed B cells in its host , but instead
persists quiescently in resting memory B cells (18). The model for EBV infection
and persistence in vivo propsed by David A. Thorley-Lawson and colleagues
maintains that EBV manipulates normal B cell biology to gain access to the
memory B cell compartment (Figure 1. 1). It does so mainly through the actions
of LMP-1 and - , which are constitutively active homologs of CD40 and the B
cell receptor (BCR), respectively (19 , 20). Thus , infected B cells receive
activation and rescue signals analogous to antigen activation. While these
signals result in continuous cell growth in vitro B cells are able to differentiate out
of cell cycle into resting memory cells in vivo enabling persistence of the virus in
Figure 1.
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Figure 1.1: Model of the proposed parallels between EBV and antigen driven B
cell activation and differentiation (from Thorley-Lawson , D.A. and Babcock , G.
1999 Life Sciences 65:1433-1453). LMP-1 and -2 are functional homologs of
CD40 and BCR , respectively, and drive activation and differentiation of infected B
cells. The ultimate result is the persistence of EBV in resting memory B cells.
EBV-associated lymphomas with gene expressionEBVpatterns
corresponding to the stages of EBV- induced differentiation are shown at the
bottom.
cell type with limited gene expression and therefore less sensitive to
immunosurveillance by T cells. A schematic diagram of the life cycle of primary
and persistent EBV infection in its host is shown in Figure 1.
2 Lytic infection
As in vitro cell systems fully permissive for lytic EBV infection have yet to
be discovered , the lytic cycle of infection can only be studied by inducing latently
infected cells into lytic replication. The lytic cycle follows the sequential
expression of immediate early (IE), early (E) and late (L) viral genes , resulting in
lysis of the infected cell and release of progeny virions. The principal known IE
genes are BZLF-1 and BRLF- , which function as viral transcription factors (17).
The E genes , which are defined by their transcription in the absence of viral DNA
synthesis , function in viral transcription , viral replication , and cell survival (17).
The viral L genes are mainly structural and involved in virion formation. One
non-structural L gene is BCRF- , which is a homolog of the human IL-10 gene
and likely functions in immunomodulation (21).
The primary cell type(s) permissive for lytic EBV infection in vivo 
unknown , but epithelial cells of the oropharynx are generally thought to be
targets of lytic infection. This issue is controversial, however , as in situ
hybridization studies have detected viral transcripts in desquamating epithelial
cells and resident B cells of the tonsilar epithelium (22). Evidence for EBV
Figure 1.
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Figure 1. 2: EBV life cycle (from Cohen J. I. 2000 N Engl J Med 343:481-492).
EBV is transmitted through saliva and infects cells of the oropharynx. It can then
initiate productive lytic infection or its latent program of infection. Infected cells
that express EBV proteins can be targets of host T cell responses; resting
memory B cells that do not express viral proteins evade host responses.
Periodic reactivation results in production and secretion of new virions into the
saliva.
infection of epithelial cells comes from the detection of EBV genome in the
epithelial cells of nasopharyngeal carcinomas (23).
3. EBV-associated malignancies
The oncogenic potential of EBV is evident in its ability to transform B cells.
In fact , EBV has been associated with an increasing number of lymphomas and
epithelial malignancies. While the role of EBV in some malignancies is well-
defined , the association of EBV with other tumors is unclear. B cell lymphomas
arising in immunocompromised hosts , such as XLP , PTLD , and AIDS patients
constitute the most apparent role for EBV in tumor pathogenesis (22). EBV is
also frequently detected in Burkitt's lymphoma, Hodgkin s disease, and
nasopharyngeal carcinoma. For these malignancies , EBV appears to act along
with other cofactors to cause disease.
EBV-associated diseases are categorized by the pattern of EBV gene
expression found in the tumors (Figure 1. 1). All tumors express EBNA- , and
Burkitt' s lymphomas (type I latency) express only this protein. Latency types II
and III express other latent proteins in addition to EBNA- , with latency type III
characterized by expression of all latent EBV proteins. Latent gene expression
of tumors has important implications for immunotherapeutic strategies to
eliminate EBV-associated malignancies.
C. Role of T cell immunity in the control of persistent viral infections
1. Murine models
Studies of viral immunity in mice have shown that T cells are key
mediators of virus control and elimination (24). Virus-specific CD8+ T cells are
able to kill virus- infected cells and secrete antiviral cytokines such as IFN-
Virus-specific CD4+ T cells can mediate antiviral effects directly, through cytokine
secretion , or indirectly by the provision of "help" to B cells and CD8+ T cells.
After resolution of acute infection , virus-specific memory CD8+ and CD4+ T cells
persist and , along with neutralizing antibody, prevent re- infection with the same
virus.
T cell immunity to lymphocytic choriomeningitis virus (LCMV) in mice has
been the subject of much investigation. As LCMV-specific CD8+ and CD4+ T
cells expand , virus is cleared. Frequencies of LCMV-specific T cells then decline
until the memory population is established. LCMV-specific CD8+ T cells expand
to higher frequencies than LCMV-specific CD4+ T cells , but both T cell
populations are retained into long-term memory.
Macrophage- and Iymphocyte- tropic strains of LCMV can cause a chronic
infection in mice , lasting up to several months (25). CD8+ T cells are an essential
component of LCMV clearance , as P2m l- mice are unable to clear either acute or
chronic LCMV infection (26). However , CD4+ T cells also constitute an important
component of the LCMV responses during chronic infection. While CD4-
depleted mice are able to clear acute LCMV infection by the parental strain , CD4
depletion during the acute phase of chronic LCMV infection results in lifelong
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viral persistence (26). Studies using CD4-deficient mice suggest that the inabiliy
of these mice to clear the virus is due to the deletion and functional
unresponsiveness of LCMV-specific CD8+ T cells (27).
Murine gammaherpesvirus (MHV)-68 also establishes a persistent
infection in mice. Resolution of acute MHV-68 infection is mediated by CD8+ T
cells (28); however, virus titers and virus- infected B cells increase over time in
CD4-deficient mice and result in death of the animals (29). Unlike chronic LCMV
infection of CD4-deficient mice , MHV-68-specific CD8+ T cells are not deleted or
functionally unresponsive (30). Secretion of IFN-y by CD4+ T cells likely plays an
important role in mediating control of persistent infection with MHV-68 (31).
2. Human viral infections
cell immunity is thought to be important in the control of persistent
infections caused by several human viruses , including human immunodeficiency
virus (HIV), hepatitis C virus (HCV), CMV, and EBV. During the acute phase of
HIV infection , the initial drop in viremia is temporally associated with the
emergence of HIV-specific CD8+ T cells (32). Sufficient immune pressure is
exerted on the virus by CD8+ T cells to result in sequence mutations allowing
escape from CD8+ T cell recognition (33). Depletion of CD4+ T cells during acute
and persistent HIV infection results in reduced ability to control both HIV and
infection with opportunistic pathogens.
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CD4+ T cell responses are believed to be particularly important for the
control of HCV infection. Strong HCV-specific CD4+ and CD8+ T cells responses
are detected during acute infection in individuals that clear the virus; these
responses also coincide temporally with clearance of virus (34). Patients that
develop a chronic infection with HCV have generally weaker and less broad
HCV-specific CD4+ T cell responses than those able to clear the virus (35 , 36).
Immunosuppressed individuals , such as transplant recipients and HIV-
infected patients , often experience CMV- and EBV-associated diseases. This
suggests that virus-specific T cell responses are very important in controlling
persistent CMV and EBV infection. In fact, adoptively transferred CTL clones
from allogeneic bone marrow donors can prevent CMV disease in transplant
recipients (37). CMV-specific CD4+ T cells also appear to be important in
preventing CMV disease in renal transplant recipients (38). EBV- induced PTLD
has also been successfully treated and/or prevented by infusions of EBV-specific
T cells (39).
Primary Immune responses against acute CMV infection have been
characterized in CMV-seronegative renal transplant recipients of seropositive
organ donors. CMV-specific CD4+ T cells, detected by intracellular IFN-
staining, peak at a median of 7 d after first detection of CMV DNA in the
peripheral blood (40). Frequencies of CMV-specific CD4+ T cells then decline
rapidly, while CMV DNA remains high for several weeks. The kinetics of CMV-
specific CD4+ and CD8+ T cell responses were further analyzed in asymptomatic
'i"'
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vs. symptomatic transplant recipients (38). For both asymptomatic and
symptomatic patients , detection of CMV DNA and CMV-specific CD8+ T cell
responses were comparable , with a median of 26-27 d for detection of CMV DNA
and 21-24 d thereafter for detection of CMV-specific CD8+ T cells. Antibody
responses were also similar in asymptomatic and symptomatic patients.
However, detection of CMV-specific CD4+ T cell responses is delayed 
symptomatic patients , with a median detection time of 39 d (vs. 10 d for
asymptomatic patients) after detection of CMV DNA. These data suggest that
CMV-specific CD4+ T cell responses are important in preventing CMV disease in
transplant recipients.
O. Acute EB V infection as a system for studying the generation and maintenance
of human T cell responses
1. Acute Infectious Mononucleosis (AIM)
Approximately 50% of individuals that experience primary EBV infection
during young adulthood present with clinical symptoms of AIM. These include
fever, sore throat, fatigue , lymphadenopathy, and splenomegaly. AIM is clinically
diagnosed by positive Monospot test and the presence of atypical lymphocytes
with the confirmation of acute EBV infection through detection of anti-EBV viral
capsid antigen IgM. Disease symptoms likely result from the vigorous T cell
response because anti-viral agents do not affect disease course (41), and
symptoms can persist long after reduction of virus load. As AIM is a clear
I .
indication of primary EBV infection , and there is a relatively high incidence of AIM
in the adolescent population , it has provided a means for studying primary EBV-
specific T cell responses.
Although symptoms of AIM indicate primary EBV infection , there is an
incubation period between virus transmission and development of clinical
symptoms , the duration of which is estimated to be between 4-6 weeks. This
incubation period , which does not commonly occur after laboratory infections of
mice, also occurs during other human virus infections and may reflect the
inoculation dose of virus in a natural infection vs. an experimental one. It is
important to note, then, that EBV-specific immune responses characterized
during the symptomatic phase of infection may not accurately represent the
earliest stages of the acute response.
2. EBV-specific CD8+ T cells
High frequencies of EBV-specific CD8+ T cells have been documented
during AIM. Although lytic and latent viral proteins are likely expressed during
primary EBV infection , early EBV-specific CD8+ T cell responses during acute
infection are directed towards lytic proteins (42-44). After resolution of the acute
infection , lytic epitope-specific CD8+ T cells decline in frequency but most remain
detectable throughout latency. Latent epitope-specific CD8+ T cells , however
are uncommonly detected in the peripheral blood at presentation with AIM (43)
but become detectable after several weeks. Frequencies of latent epitope-
. specific CD8+ T cells are generally lower than frequencies of lytic epitope-specific
CD8+ T cells during AIM and remain stable over long periods of time. A graphical
representation of the pattern of EBV lytic and latent epitope recognition by CD8+
T cell over the course of infection is shown in Figure 1.4.
EBV-specific CD8+ T cells play an important role in maintaining EBV
latency. Under circumstances of T cell immunosuppression , EBV- induced B cell
Iymphoproliferative disorders can ensue. Treatment of EBV-induced
Iymphoproliferative disorders with infusions of in vitro generated EBV-specific
CD8+ T cell lines can elicit remission of lymphoma (45 , 46).
3. EBV-specific C04+ T cells
While EBV-specific CD8+ T cell responses have been well-documented
EBV-specific CD4+ T cell responses have been less well studied , especially
during AIM. Several groups have derived EBV-specific CD4+ T cell lines from
latently- infected individuals and have used these lines to determine the EBV
protein and epitope specificity of CD4+ T cell responses (47-50). For example
EBNA-1- and EBNA-3C-specific CD4+ T cell lines have been generated from
healthy, EBV seropositive individuals (47 , 48). In addition , Leen and colleagues
have identified HLA class II-restricted EBNA- , EBNA- , LMP- , and LMP-
epitopes using ELiSPOT assays (51). EBNA-1-specific CD4+ T cell clones have
been shown to inhibit outgrowth of EBV- infected B cells in vitro (52). This is of
interest , as all EBV-associated tumors express EBNA-
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Figure 1. 4: EBV antigen-specific recognition by CD8+ T cells during acute and
latent infection (from Catalina M. D. 2001 J /mmuno/167:4450-4457). Previously
defined , HLA class I-restricted EBV epitopes were used to stimulate whole blood
of individuals with acute or persistent EBV infection , and intracellular IFN-y was
measured. Percentages of individuals with detectable frequencies of IFN-
producing cells are shown. Numbers represent n values.
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Whereas most studies have defined CD4+ T cell responses specific for
latent antigens during persistent EBV infection , little is known about the timing,
magnitude , breadth , or specificity of CD4+ T cell responses during acute EBV
infection. White et al. have reported the isolation of a BHRF-1-specific CD4+ CTL
clone from the peripheral blood of an AIM patient (50), but more direct
characterization of EBV-specific CD4+ T cell responses and their relationship to
CD8+ T cell responses is limited.
E. Thesis Aims
The objective of this thesis dissertation was to examine EBV-specific
CD4+ T cell responses over the course of acute infection. In an effort to gain
insight into their in vivo effector functions, experiments were designed 
characterize EBV-specific CD4+ T cells ex vivo rather than using previously-
employed in vitro culture approaches.
In Chapter 3 , short in vitro stimulation assays followed by intracellular
cytokine staining are used to characterize the timing, magnitude , and antigen-
specificity of CD4+ T cells over the course of primary EBV infection.
hypothesize that, similar to EBV-specific CD8+ T cell responses during AIM
EBV-specific CD4+ T cell responses will be directed predominantly toward lytic
proteins. However, we find that both lytic and latent protein-specific CD4+ T cells
are readily detected at presentation with AIM but decline rapidly thereafter.
Responses to BZLF- , BMLF- , and EBNA-3A are more commonly detected
than responses to EBNA-1. Responses decline rapidly following presentation
with AIM and are undetectable by 6 mo to 1 yr thereafter.
The relationship between EBV-specific CD4+ T cells and both EBV-
specific CD8+ T cells and blood viral load over the course of AIM are examined in
Chapter 4. We hypothesize , based on observed differences between EBV Iytic-
and latent-specific CD4+ and CD8+ T cell responses early in AIM , that CD4+ and
CD8+ T cell responses directed against the same lytic protein may also differ.
Peptide-based assays are used for concurrent analysis of the timing, magnitude
and specificity of BZLF-1-specific CD4+ and CD8+ T cell responses. Our data
show that BZLF-1-specific CD4+ T cell responses tend to peak earlier and at
lower frequencies than BZLF-1-specific CD8+ T cell responses. EBV-specific
CD4+ T cell responses correlate with blood viral load at presentation with AIM
and both decline in parallel over time.
Because of the rapid decline in EBV-specific CD4+ T cell responses
following AIM , we further investigate their phenotypic and functional capabilities
in Chapter 5. In order to test the hypothesis that intracellular IFN-y secretion
assays may underestimate EBV-specific CD4+ T cell frequencies , direct ex vivo
staining with HLA class II tetramers is used. We report the detection of high
frequencies of BZLF-1 epitope-specific CD4+ T cells at presentation with AIM but
a significant reduction in the frequencies by 6 wk following presentation , despite
persistently high peripheral blood viral loads. The frequencies of tetramer-
staining cells exceed the frequencies of IFN-y-secreting cells , and tetramer-
staining cells proliferate poorly in vitro. We propose that our data suggest a
relationship between high viral burden and impaired virus-specific CD4+ T cell
responses.
CHAPTER II
MATERIALS AND METHODS
A. Patient Population.
Individuals presenting to the clinic at the University of Massachusetts at
Amherst Student Health Service (Amherst , MA) with clinical symptoms consistent
with acute infectious mononucleosis and a positive monospot test were recruited
for study. Following informed consent , 50ml of blood was collected at several
time points , both at or shortly following presentation with symptoms, and at 6 mo
to 1 yr thereafter. Acute EBV infection was confirmed by the detection of IgM
antibodies to the EBV viral capsid antigen in patient sera.
Healthy EBV-seropositive and -seronegative donors were also recruited
for study. EBV serological status was determined by the presence or absence of
IgG antibodies to the viral capsid antigen in serum. Following informed consent
blood (-10ml) was collected periodically from these donors. All studies were
approved by the Human Subjects Committee at the University of Massachusetts
Medical School (Worcester , MA).
B. HLA typing.
HLA class II typing was determined by PCR. DNA was isolated from
approximately 5 X 10 cells or 200111 whole blood using the QIAamp DNA Mini kit
(Qiagen , Valencia , CA). For low resolution HLA-DR typing, the DRB SSP kit was
used (Biotest Diagnostics , Denville , NJ). For high resolution typing, the Olerup
DRB1*01 SSP kit was used (Genovision , West Chester , PA).
C. Synthesis of GST-fusion proteins.
The plasmid encoding GST-tagged BZLF-1 was generously provided by
Shannon Kenney (University of North Carolina , Chapel Hill, NC). Genes
encoding BMLF- 1 (aa 1-438), EBNA- 1 (aa 363-641), and EBNA-3A (aa 403-812)
were PCR amplified from B95. using the following primer sets: 5'
CGCGGGA TCCCCA TGGAGGGCAGCGAAGAA- and
CGCGCAA TTGTT A TTGA TTT AA TCCAGGAAC- for BMLF-
CGCGGGA TCCCCGGGGGAAGTCGTGAAGA- and
CGCGGAA TTCTT ACTCCTGCCCTTCCTCACCC- for EBNA- and
CGCGGGA TCCCCGT AGAACCCGTCCCTGTC- and
CGCGGAA TTCTT AGGCCTCA TCTGGAGGA TC-3' for EBNA-3A. The amplified
genes were cut by appropriate restriction enzymes and ligated into the multiple
cloning site of the GST expression vector, pGEX-3X (Amersham Pharmacia
Biotech , Piscataway, NJ) to create an N-terminal GST fusion. Plasmids were
used to transform E. coli strain BL21 DE3RP (Stratagene, La Jolla , CA). This
strain was also transformed with the pGEX-3X plasmid containing no insert for
purification of GST. Transformed clones were grown to midlog phase at 37
and induced with 0.6mM isopropyl-p-thiogalactosidase for 2-3h. Bacteria were
resuspended in buffer containing protease inhibitor (50mM Tris HCL 25%
sucrose , 1mM EDTA, 0.2mM phenylmethylsulfonyl fluoride , pH 8) and lysed by
the sequential addition of 1 mg/ml lysozyme , 2mg/ml DNase I , 1 M MgCI , and
lysis buffer (50mM Tris-HCL (pH 8), 1% Triton X-100 , 100mM NaCI , 1% Sodium
deoxycholate). Lysates were snap frozen in liquid N , clarified after thawing by
centrifugation at 17,400 x g, and incubated with glutathione sepharose 4B
(Amersham Pharmacia Biotech , Piscataway, NJ) overnight at 4
GST and GST-fusion proteins were purified according to manufacturer
instructions using a batchwise method with small modifications. Suspensions
were centrifuged to sediment the matrix , and the supernatants were removed.
The glutathione sepharose 4B was washed with cold PBS until OD28o of the wash
buffer was oe 0.010. Protein was eluted with elution buffer (50mM Tris-HCL
10mM reduced glutathione , pH 8) and PMSF was added at a final concentration
of 0. 1 mM. Protein from pooled eluates was quantified using Bradford Assay and
analyzed by SDS-PAGE and Western blot. Protein preparations were further
purified over polymyxin B columns (Pierce , Rockford , IL) to remove endotoxin
according to manufacturer s instructions. Concentrated stocks were stored at -
C. Working stocks for immunology assays were diluted to 1 mg/ml in RPMI
and stored at -
D. Peptides.
Sixteen 25-mer, overlapping (10aa) peptides spanning the BZLF-1 protein
and additional truncation peptides were synthesized for epitope mapping
(Peptide Core Facility, UMMS). Peptides were dissolved in DMSO and stored at
C. Working stocks were further diluted in RPMI to a final concentration of
1 /lg/ tI and stored at 4 C. Peptide sequences are listed in Table 4. 1. As all
patients were HIV-negative , the A2-restricted Gag epitope (SL YNTVATL) was
used as a negative control. The H LA-DR 1-restricted peptide epitope
QHYREVAAKSSE (Genemed Synthesis
, Inc. , South San Francisco , CA) was
dissolved in water and used for either HLA class" tetramer production or diluted
to 1/lg//l1 for stimulation of cells.
E. Antigen and peptide stimulation of cells.
Heparinized , fresh whole blood or cryopreserved PBMC (0. 5ml) was
incubated with 20/lg/ml GST or GST-fusion protein or 10/lg/ml peptide at 37 C in
5% CO for a total of 6 h. Except where noted , 3/lg/ml each of anti-CD28 + anti-
CD49d (BD PharMingen , San Diego , CA) was added for costimulation. As a
positive control, staphylococcal enterotoxin B (SEB) (Toxin Technology,
Sarasota , FL) at 2/lg/ml was used. GolgiPlug (BD PharMingen San Diego , CA)
was added for the final 4 h of incubation. Comparable responder cell frequencies
were obtained using either fresh whole blood or cryopreserved cells as starting
material.
F. Intracellular cytokine staining.
Intracellular staining for cytokine production was performed as previously
described (53) with minor modifications. Following stimulation , EDTA was added
at 2mM and the cells were vortexed repeatedly for 15 min. Red cells were lysed
using FACS Lysing Solution (BD Biosciences , San Diego , CA) and washed in
PBS containing 1 % fetal calf serum (FCS). Cells were then permeablized in
FACSPerm (BD Biosciences, San Diego , CA), washed , and stained with a
cocktail of antibodies appropriate for the experiment, including: CDS-FITC
(Sigma-Aldrich , St. Louis , MO), CD4-PerCP , CD4-APC , CD3-PerCP , CD69-
(all BD Biosciences), CD4- , CD45RO-FITC , CD45RA-FITC , IFN- APC , TNF-
APC , IL- APC , IL- , IL- , mip-1a- , and mip-1 p-PE (all 
PharMingen).
Cytokine-secreting cells were analyzed by four-color flow cytometry on a
BD Biosciences FACSort with added laser and CellQuest software (BD
Biosciences , San Jose , CA). Isotype control antibodies and appropriate positive
and negative controls were used to define cytokine-secreting populations.
Approximately 50 000-100 000 events were collected through the lymphocyte
gate as determined by forward vs. side scatter pattern. For cytokine secretion
analysis in response to GST-fusion proteins , IFN-y was plotted vs. CD69 using a
CD4+CD45RO+ gate. No cytokine production was detected by CD4+CD45RO-
cells in our assays. Frequencies of IFN-y-secreting cells that were 2 SD above
the mean background response to GST alone were considered significant
(:;0. 06%). Cytokine production was not detected in response to EBV proteins in
EBV-seronegative individuals. Frequencies of IFN-y-secreting cells in response
to overlapping BZLF- 1 peptides were determined by plotting IFN-y vs. CD69 after
gating on CD4+ or CD8+ populations. Frequencies of cytokine secreting cells that
were 2 SD above the mean background response to the A2-Gag peptide were
considered significant (::0.03% for CD4+ T cells; ::0.04% for CD8+ T cells). For
cytokine secretion analysis in response to the QHY peptide , cytokine was plotted
vs. CD4 using a CD3+ gate. Frequencies of cytokine secreting cells were
determined by subtracting the background response to the A2-Gag peptide.
G. Cytokine staining of tonsil cells.
Tonsils destined to be discarded from individuals undergoing routine
tonsillectomy were obtained as approved by the Human Subjects Committee at
the University of Massachusetts Medical School (Worcester, MA). Cells were
teased from the tonsil tissue using a scalpel , filtered through a 70l-m nylon cell
strainer (BD Falcon , Franklin Lakes , NJ), and washed 3X in RPMI 1640 media
supplemented with 10% FCS , 2mM L-glutamine , and 0. 01mg/ml gentamicin (R10
media). Cells were cryopreserved until use.
Freshly thawed tonsil cells were stimulated with GST-fusion proteins as
above , except the total incubation time was increased to 18 h , with the addition of
GolgiPlug for the final 16 h. Intracellular IFN-y production was detected and
analyzed as above.
H. Real-time PCR quantification of EBV viral load.
EBV DNA copy frequency was estimated uSing a modification of the
previously described real-time TaqMan PCR method for EBV quantification (54)
or using LightCycier PCR. B lymphocytes were enriched either from whole blood
using the RosetteSep protocol (StemCell Technologies Inc. , Vancouver, BC
Canada) or from freshly thawed PBMC by MACS using a B cell isolation kit
(Miltenyi Biotec , Auburn , CA). Genomic DNA was extracted using the DNAeasy
kit (Qiagen , Valencia , CA).
The number of EBV copies was determined using the LightCycier-EBV
Quantification Kit (Roche Diagnostics Corporation , Indianapolis , IN) or Taqman
method. For the Taqman PCR method , the oligonucleotide primer-pairs amplify
conserved sequences of the BALF5 region that encodes the viral DNA
polymerase within the EBV genome, and their sequences are as follows: forward
primer CGGAAGCCCTCTGGACTTC- reverse primer
CCCTGTTT A TCCGA TGGAA TG- fluorogenic probe (5'
TGTACACGCACGAGAATGCGCC- ), which will hybridize to a sequence
located within the region amplified by the forward and reverse primers , was
synthesized with a FAM reporter molecule attached to the 5' end and a TAMRA
quencher linked at the 3' end. The PCR mixture contained either 100ng or 200ng
of genomic DNA in a 50ul reaction volume containing 10 mM Tris-HCI , pH 8. 3; 50
mM KCI , 5 mM MgCI ; 10mM EDT A; 100 uM each of dATP , dCTP , dGTP , and
dTTP; 0.2mM of each primers; 0. 1 mM fluorogenic probe; and 1.25U of AmpliTaq
Gold DNA polymerase (PE Applied Biosystems, Foster City, CA). The
amplification was performed in ABI TaqMan 7700 Sequence Detector
thermocycler (PE Applied Biosystems) according to the following cycling
parameters: 10 min at 95 C to activate the AmpliTaq Gold DNA polymerase
followed by 45 cycles of 15 sec at 95 C and 1 min at 62 C. DNA extracted from
cells from EBV-seropositive and -seronegative donors were included as
positive and negative controls , respectively.
Serially diluted control plasmid (from 10 to 10 copies) containing a single
copy of the BALF5 amplicon generated by the forward and reverse primers was
included in each PCR assay. The threshold cycle (CT) value corresponding to
the point at which the real-time fluorescence exceeded 10 times the SD of the
baseline for each sample was calculated for each sample. The CT values were
then plotted against copy number to construct the standard curve , and from the
CT values of test samples the EBV copy number was calculated using the
software for data analysis (Sequence Detector version 1. , PE Applied
Biosystems). Samples with CT values that exceeded 45 cycles in our conditions
of the assay were considered negative for EBV.
To determine the cellular equivalents of template DNA within each test
sample , real-time PCR was performed on aliquots of template DNA to amplify a
region within the duplicate-copy cellular chemokine receptor gene , CCR5. The
primers used were 5' - GCTGTGTTTGCGTCTCTCCCAGGA-3' (forward) and 5'
CTCACAGCCCTGTGCCTCTTCTTC- (reverse). The corresponding
fluorogenic oligonucleotide probe used for the Taqman method was 5' FAM-
AGCAGCGGCAGGACCAGCCCCAAG- T AMRA 3' Alternatively, LightCycler
FastStart DNA Master SYBR Green I (Roche Diagnostics Corporation
Indianapolis , IN) was used to quantify CCR5. Serially diluted plasmid containing
a single copy of the CCR5 gene was used to generate the standard curve and
the CCR5 copy number in the sample was determined. The number of cellular
equivalents was then calculated and the EBV copy frequency in the population of
Iymphocytes in each test sample was expressed as copies of EBV genome per
B cells. Each sample was tested in triplicate , and the mean of the three
values was considered for quantifying the EBV load.
I. Generation and maintenance of EBV-speeific CD4+ T eel/lines.
Peptide-specific cell lines were generated using one of two methods. The
first method involved peptide-specific stimulation and expansion. Cells were
incubated at high cell concentration in a small volume with 100!Jg/ml peptide at
C in 5% CO for 1h. The cells were then washed and plated in R10 media.
After 2 d incubation , 50U/ml rhlL-2 (Roche Diagnostics Corporation , Indianapolis
IN) was added. Cells were maintained and expanded as necessary in R10
media supplemented with rhIL- Peptide specificity was confirmed by
intracellular IFN- staining in response to appropriate peptide. Cell lines
generated in this manner generally ceased dividing 2-4 wk following initial
stimulation.
Alternatively, non-specific stimulation followed by isolation and expansion
of peptide-specific cells was also used to generate peptide-specific CD4+ T cell
lines. Cells were plated at 2 X 10 /ml in R10 media supplemented with 50U/ml
rhlL-2 and 1/lg/ml of the bispecific monoclonal antibody anti-CD3:CDS (provided
by Johnson Wong, Massachusetts General Hospital , Boston , MA). This antibody
leads to an expansion of CD3+CD4+ T cells with a selective loss of CDS+ T cells
(55). After a sufficient number of CD4+ T cells were expanded , the cells were
stimulated with peptide , and IFN-y-secreting cells were isolated by MACS using
the IFN-y secretion assay-cell enrichment and detection kit (Miltenyi Biotec
Auburn, CA). Isolated , peptide-specific cells were plated in R10 media
supplemented with 50U/ml rhlL-2 and irradiated , nonautologous PBMC (feeder
cells). Cells were maintained and expanded, as necessary, in rhIL-
supplemented R10 media and peptide-specificity of the cell line was confirmed
using intracellular IFN- staining response to peptide stimulation.
Subsequently, cells were restimulated every 2-3 wk in rhIL-2-supplemented R10
media containing feeder cells (cell line: feeder=1 :3) and anti-CD3 (OKT-
American Type Culture Collection , Manassas , VA). Cell lines generated in this
manner could be maintained up to several months. Aliquots of cells were
cryopreserved periodically for future use.
J. HLA restriction analysis.
In order to determine the HLA restriction of peptide-specific responses
HLA-matched and -mismatched BLCL were pulsed with peptide and used to
stimulate peptide-specific CD4+ T cell lines for analysis of intracellular IFN-
production. BLCL used were: LG2 (generously provided by Larry Stern , UMMS),
which is homozygous for DRB1*0101 and E1135 (derived from an AIM patient),
with genotype HLA-DRB1*0402
, *
1302; -DOB1*0302
, *
06041. BLCL were
incubated with 1 M peptide for 1 h at 37 C in 5% CO . Peptide-pulsed BLCL
were then washed 3X in R10 and combined with CD4+ T cells at a ratio of 10:1 (T
cell line: BLCL) in a total volume of 1 ml R10 media supplemented with g/ml
each of anti-CD28 + anti-CD49d. Some tubes were also incubated with anti-
HLA-DR blocking antibody (BD PharMingen , San Diego , CA) or isotype control
(Research Diagnostics Inc. , Flanders, NJ) at 5 g/ml to differentiate between
HLA-DR and -DP- or -DO-restricted responses. Cells were incubated at 37 C in
5% CO for a total of 7 h. GolgiPlug was added for the final 6 h of incubation.
Following incubation , cells were placed at 4 overnight. Intracellular IFN-
staining was performed the following day as above.
K. HLA class /I tetramers.
Biotinylated monomers of HLA-DRA1*0101/DRB1*0101 bound to either
QHY peptide or Flu-HA peptide were generously provided by Larry Stern
(UMMS). The monomer was tetramerized for use as a staining reagent by the
stepwise addition of streptavidin(SA)-PE (Biosource, Camarillo, CA). The
r=.
optimal SA-PE: DR1 monomer ratio was determined as previously described (56)
by titration followed by staining of the QHY-specific CD4+ T cell line. As a
negative control , either DR1/Flu-HA tetramerized in an identical manner as
DR1/QHY tetramer or PE-conjugated DR1/Clip tetramer was used (Beckman
Coulter , Fullerton , CA).
Whole blood and cell lines were stained as described (57) with a few
modifications. Cells were stained with 1 O I tetramer in a total volume of 200 1 in
ml polystyrene round bottom FACS tubes at 37 C in 5% C02 for 2h. Following
tetramer staining, cells were placed on ice and stained for 20 min with CD3-
PerCP, CD4-APC (both BD Biosciences), and CDS-FITC (Sigma-Aldrich),
CD45RA-FITC , CD45RO-FITC, CD11a-FITC , CD25-FITC, CD27-FITC, CD2S-
FITC, CD62L-FITC, CD95-FITC or CD154-FITC (all BD PharMingen).
Appropriate isotype control antibodies were also included for gating purposes.
For some experiments , cells were stained with CD4-PerCP (BD Biosciences) and
combination of FITC- and APC-conjugated CD45RA, CD45RO, CD11 a
CD62L , and CD95 antibodies (BD PharMingen).
After antibody staining, cells were lysed with FACS Lysing Solution and
washed twice with cold PBS containing 1 % FCS. Cells were then fixed with 1 %
paraformaldehyde and analyzed by four-color flow cytometry. Approximately
150 000 events were collected through a live lymphocyte gate as determined by
forward vs. side scatter pattern. For tetramer-binding frequency analysis , CD4
was plotted vs. tetramer on CD3+ gated cells. Quadrants were set using the
negative control DR1/Clip tetramer. For phenotypic analysis of tetramer-binding
cells , phenotypic marker was plotted vs. tetramer on CD3 CD4+ gated cells.
Quadrants were set using DR1/Clip tetramer, isotype control antibodies , and
careful assessment of positively- and negatively-staining non-tetramer-binding
populations.
L. Cellular proliferation measured by CFSE
Cryopreserved PBMC were thawed rapidly and washed in R10 media and
then washed twice in PBS. CFSE (Sigma , St. Louis , MO) was added at a final
concentration of 0.01 JlM at room temperature for 5 min to label all cells. FCS
was added at 20% (v/v) to stop the reaction and the cells were washed twice in
2% FCS/PBS. Cells were then plated at 1-2 X /ml in R 10 media
supplemented with 10Jlg/ml peptide as indicated , with or without 10U/ml rhlL-
(Roche Diagnostics Corporation , Indianapolis , IN) in 24-well plates. As a positive
control , anti-CD3 (OKT- , American Type Culture Collection , Manassas , VA) and
IL-2 were added. Approximately 5 X cells were harvested at several
timepoints thereafter and stained with DR 1/QHY tetramer as above to measure
proliferation of QHY-specific CD4+ T cells indicated by reduced CFSE
fluorescence.
CHAPTER II
EBV-SPECIFIC CD4+ T CELLS TARGET BOTH LYTIC AND LATENT EBV
PROTEINS EARLY IN ACUTE INFECTIOUS MONONUCLEOSIS
A. Introduction.
Prior to these studies little was known about the timing, magnitude
breadth , or specificity of CD4+ T cell responses during acute EBV infection. Most
of the previous reports described EBV-specific CD4+ T cell responses using long-
term in vitro culture methods. Studies generally focused on responses targeting
EBV latent proteins in individuals with established infection. However, much
more was known about EBV-specific CD8+ T cell responses over the course of
acute EBV infection. Namely, lytic epitope-specific CD8+ T cells were detected
more commonly and at generally higher frequency than latent epitope-specific
CD8+ T cells early in AIM. Over time , lytic epitope-specific CD8+ T cells declined
in frequency and latent epitope-specific CD8+ T cells were more frequently
detected.
Based on this differential pattern of antigen recognition by CD8+ T cells
during acute EBV infection , we hypothesized that there may be differential
antigen expression or processing and presentation of lytic and latent EBV
proteins. In order to better characterize EBV-specific CD4+ T cells during AIM
and test whether there is a similar pattern of lytic and latent antigen recognition
by CD4+ T cells over the course of AIM , EBV lytic and latent protein antigens
were produced for use in stimulation assays to detect antigen-specific IFN-
production by CD4+ T cells in the peripheral blood of individuals with AIM.
B. EBV lytic and latent protein antigens.
Since our lab (43) and others (42 , 44) have previously shown that EBV
lytic (BZLF- , BMLF-1) and latent (EBNA-3A) proteins are commonly recognized
by CD8+ T cells , and recognition of EBNA-1 by CD4+ T cells had been recently
reported (48 , 51), we prioritized these proteins for study. Truncations of the
genes encoding these proteins were cloned into a GST expression vector
produced in E. coli and purified. A Western blot of the GST-fusion proteins is
shown in Figure 3. 1. In addition to the band visualized at the expected molecular
weight for each full-length fusion protein , bands of intermediate size are also
present, indicating the production of incomplete fusion proteins. As the proteins
were ultimately destined for uptake , processing, and presentation by antigen
presenting cells in our stimulation assays , the presence of truncated proteins
within the antigen preparations was acceptable. In the last step of purification
endotoxin was removed to reduce nonspecific stimulation. GST alone was
purified in an identical manner for use as a negative control stimulus.
Figure 3.
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Figure 3. 1: Western blot of purified GST-tagged EBV proteins. Proteins were
run on SDS-PAGE gel , transferred to a nitrocellulose membrane , and blotted with
anti-GST antibody. Molecular weight markers , in kDa , are shown to the left.
Z=GST-BZLF- (-53kDa), M=GST-BMLF1 aa1 438 (-74kDa), E1=GST-EBNA-
1aa363-641 (-57kDa), E3A=GST-EBNA- aa403 812 (-71kDa), GST (-26kDa).
C. Detection of EBV-specific CD4+ T cell responses early during AIM.
The frequencies of EBV-specific CD4+ T cells were measured in the
peripheral blood of individuals at and following presentation with AIM using
intracellular IFN-y staining following in vitro stimulation with each soluble protein
(Figure 3.2a). SEB was used as the positive control in these studies. Cytokine
production was not detected following the in vitro stimulation of whole blood from
healthy, EBV seronegative adults (Figure 3.2b). At presentation with AIM , EBV-
specific CD4+ T cells were detected in all individuals (Table 3. 1). Eight (89%) of
9 individuals had detectable responses to two or more proteins. Responses to
BZLF-1 were detected most frequently (17 of 17 individuals studied). BMLF-
and EBNA-3A-specific CD4+ T cell responses were each detected in the
peripheral blood of 7 (78%) of 9 individuals studied. By contrast, EBNA- 1-specific
CD4+ T cells were detected in only 3 (33%) of 9 individuals studied.
Frequencies of CD4+ T cells producing IFN-y in response to each EBV
protein are shown in Figure 3. 3. At presentation , the frequencies of CD4+ T cell
responses to BZLF-1 were generally higher than those directed at the other
proteins. BZLF-1-specific CD4+ T cell responses were measured at frequencies
that ranged from 0.08% to 1.75% of CD4+CD45RO+ cells (median = 0. 31 %).
BMLF-1-specific CD4+ T cell responses were measured at frequencies ranging
from 0.07% to 0.54% (median = 0.27%), while EBNA-3A-specific CD4+ T cell
responses ranged from 0.08% to 0.34% (median = 0. 16%). EBNA-1-specific
CD4+ T cell responses ranged from 0. 1 %- 36% (median = 0.23%).
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Figure 2: Intracellular IFNy staining of EBV-specific CD4+ T cells. Whole
blood from a patient presenting with AIM (a) or a healthy EBV seronegative adult
(b) was stimulated with GST-tagged fusion proteins BZLF- , BMLF- , EBNA-
or EBNA-3A or GST alone as a negative control. Stimulation with SEB served as
positive control. Antigen-specific cells are expressed as a percent of
CD4+CD45RO+ cells co-expressing CD69+ IFN-
Table 3.
Visit BZLF- BMLF- EBNA- EBNA-
Presentation 100%(17/17) 78%(7/9) 33%(3/9) 78%(7/9)
3wk 72%(13/18) 56%(5/9) 33%(3/9) 56%(5/9)
6wk 61%(11/18) 33%(3/9) 22%(2/9) 33%(3/9)
6mo 25%(4/16) 0%(0/8) 0%(0/8) 0%(0/8)
1yr 0%(0/11) 0%(0/5) 0%(0/4) 0%(0/5)
Table 3.1: Percentage of individuals with detectable EBV-specific CD4+ T cell
responses over the course of AIM. In parenthesis , the numerator indicates the
number of individuals with detectable CD4+ T cell responses; the denominator
indicates the total number of individuals tested at each visit.
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Figure 3: EBV-specific CD4+ T cell frequencies following presentation with
AIM. Frequencies of IFN- producing cells in response to BZLF-1 (upper left),
BMLF-1 (lower left), EBNA-1 (upper right), and EBNA-3A (lower right) were
calculated as in Fig. 3.2 for each individual and plotted versus study timepoint.
Each character represents an individual patient. Solid lines indicate median
responder cell frequency of detectable responses. The hatched line in each plot
represents the limit of detection (0. 06% of CD4+CD45RO+ cells).
D. EBV-specific CD4+ T cell responses decline rapidly following acute infection.
Blood was collected at sequential timepoints up to 1 yr following
presentation with AIM to determine the stability of EBV-specific CD4+ T cell
responses over time following acute EBV infection. As shown in Table 3. 1 and
Figure 3. , the numbers of individuals responding and the responder cell
frequencies of BZLF- , BMLF- , EBNA- , and EBNA-3A-specific CD4+ T cells
were highest within 3 wk of presentation with AIM and declined rapidly over time
following primary infection. By 6 wk following presentation , BZLF-1 responses
were detected in only 61 % of individuals , BMLF-1 and EBNA-3A responses in
only 33% of individuals, and EBNA-1 responses in only 22% of individuals.
Median responder cell frequencies in individuals with detectable responses
dropped to 0. 12% 07% 09% , and 0. 09% for BZLF- , BMLF- , EBNA- , and
EBNA- , respectively by the 6 wk timepoint. EBV-specific CD4+ T cells were
undetectable in most individuals by 6 mo and in all individuals by 1 yr following
AIM. Of interest , EBV-specific responses were not detected in any of twelve EBV
seropositive healthy adults tested (data not shown).
To determine whether other cytokines were produced in response to these
EBV antigens over the course of infection , we assayed for IL-4 production by
intracellular cytokine staining and by ELiSPOT assay. IL-4 production was not
detected by intracellular cytokine staining or ELiSPOT assay in response to 
vitro stimulation with BZLF- , BMLF- , EBNA- , or EBNA-3A proteins at any time
point from presentation through convalescence (data not shown).
E. Rare detection of EBV-specific C04+ T cell responses from tonsil cells.
Because EBV-specific CD4+ T cells were readily detected in the peripheral
blood during AIM but not detected after resolution of acute infection
hypothesized that the cells could be trafficking to tissues. As the tonsils are the
site of initial infection and periodic reactivation of the virus and are therefore a
logical homing site for virus-specific cells , we obtained tonsils from individuals
undergoing routine tonsillectomy to determine whether we could detect EBV-
specific CD4+ T cell responses. EBV infection of tonsil cells was determined by
real-time Taqman PCR. Nine of 13 tonsil samples (69%) were EBV positive by
PCR (Table 3.2).
Stimulation of isolated tonsil cells with the EBV fusion proteins for a total
of 6 hr did not lead to significant frequencies of CD4+ cells producing IFN-
however, a few samples showed a low frequency of IFN- producing CD4+ T
cells that fell just below our level of detection. Therefore , the total incubation
time was increased to 18 hr to allow longer stimulation and potentially increase
detection of EBV-specific CD4+ T cells. After incubation for the increased time
period , we were able to detect significant IFN-y production from only 1 of 9 (11 
EBV positive tonsil samples. This response was specific for EBNA- 1 (Figure
3.4). As negative controls , IFN-y production was not detected from EBV negative
samples or in response to GST alone (Table 3. 2 and Figure 3.4).
Table 
EBV Sample EBV DNA Copies/1 0 EBV-specific CD4+ T
Status Cells Cell Response?
EBV+ T -01 0 15E+02 Yes
011 11E+04
012 11 E+02
015 03E+02
016 84E+03
T -017 78E+01
020 32E+03
021 1.45E+04
T -023 27E+05
EBV - T -014 OOE+OO
T -022 OOE+OO
T -024 OOE+OO
T -025 OOE+OO
Table EBV-specific CD4+ T cell responses from isolated tonsil cells.
Intracellular IFN-y was measured as in Fig. 3.4 and responses ::0. 06% were
considered positive. EBV load was measured by Taqman PCR.
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Figure 3. 4: Intracellular IFNy staining of EBV-specific CD4+ T cells from tonsils.
Cells isolated from an EBV PCR+ (a) or EBV PCR- (b) tonsil were stimulated with
GST-tagged fusion proteins BZLF- , BMLF- , EBNA- , or EBNA-3A or GST
alone as a negative control for 18 h. Antigen-specific cells are expressed as a
percent of CD4+ cells co-expressing CD69+ IFN-
F. Discussion
In this chapter, the magnitude , specificity, and kinetics of circulating EBV-
specific CD4+ T cells were measured from the peripheral blood of individuals
over the course of AIM. We hypothesized that differential recognition of lytic and
latent EBV proteins by CD8+ T cells reflected differences in the presentation of
these proteins to T cells and therefore we would detect a similar pattern of
recognition by CD4+ T cells over the course of AIM. CD4+ T cells were
stimulated with both lytic and latent EBV protein antigens to detect intracellular
IFN-y production. In contrast with previous studies demonstrating differential
recognition of lytic and latent antigens by EBV-specific CD8+ T cells early in AIM
CD4+ T cell responses specific to both lytic and latent EBV proteins were
detected at presentation with AIM. These results suggest that lytic and latent
antigens are expressed very early during infection but are differentially
recognized by CD4+ and CD8+ T cells. Responses to BZLF- , BMLF- , and
EBNA-3A were more commonly detected than responses to EBNA-
Responses were highest at presentation with AIM but declined rapidly thereafter
and were undetectable by 6 mo to 1 yr after presentation.
Because we could not detect EBV-specific CD4+ T cells in the peripheral
blood during viral latency, we hypothesized that they were homing to the tonsil.
However, we were unable to detect EBV-specific CD4+ T cells in the majority of
tonsil samples from individuals with EBV infection. Although these results do not
support this hypothesis, it is possible that another method , such as direct
_..._---- ---
staining, may be required for detection of EBV-specific CD4+ T cells in tonsil
cells.
- -
CHAPTER IV
CD4+ AND CD8+ T CELL RESPONSES AGAINST AN IMMEDIATE EARLY
EBV PROTEIN DIFFER IN MAGNITUDE , KINETICS , SPECIFICITY , AND
RELATIONSHIP WITH VIRAL LOAD OVER THE COURSE OF AIM
A. Introduction
In the previous chapter, we found that CD4+ T cell responses , unlike CD8+
cell responses , were directed against EBV lytic and latent proteins. This
suggests that the priming of EBV antigen-specific CD4+ and CD8+ T cells may
differ. We therefore hypothesized that differences would be observed between
CD4+ and CD8+ T cell responses directed against the same EBV protein.
Additionally, we proposed that we would detect differences in the relationship
between EBV-specific CD4+ and CD8+ T cell responses and viral load.
B. Detection of EBV-specific CD4+ and CD8+ T cell responses during AIM
In order to examine potential relationships between the magnitude
kinetics , and specificity of EBV-specific CD4+ and CD8+ T cell responses over the
course of AIM , intracellular cytokine staining was performed after stimulation with
overlapping peptides spanning the immediate early protein , BZLF-1 (peptide
sequences are listed in Table 4. 1). This lytic cycle protein was chosen because
of our previous results showing that CD4+ T cells commonly target BZLF-1 during
.
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Table 4. 1: Overlapping BZLF-1 peptides. Intracellular IFN-y production by CD4+
cells and CD8+ cells in response to each peptide was measured in 6 patients with
AIM over the first 6 wk of infection. A detectable CD4+ T cell response is
denoted with a 4; a detectable CD8+ T cell response is denoted with an 8. An
asterisk indicates a response to both the indicated peptide and the next
consecutive peptide , suggesting the epitope may reside in the shared amino acid
overlap.
AIM. Overlapping peptides were used as stimulation because the fusion protein
did not stimulate CD8+ T cells very well. Frequencies of peptide-specific cells
were determined by IFN-y production in response to each peptide after gating on
CD4+ or CD8+ cells. As depicted in Tables 4. 1 and 4. , BZLF- 1-specific CD4+
and CD8+ T cell responses were detected in all six individuals studied.
C. Magnitude of BZLF- 1-specific CD4+ and CD8+ T cell responses during AIM.
In order to quantify the response to the entire BZLF- 1 protein , responses to
individual , nonconsecutive peptides were added together. The sum of the
peak frequencies of BZLF- 1 peptide-specific CD8+ T cells were substantially
greater than the sum of the peak frequencies of BZLF-1 peptide-specific CD4+ T
cells in 4 of 6 individuals (Table 4. 2) over the first 6 wk of AIM. BZLF-1-specific
CD4+ T cell responses measured by this method ranged from 0.06% to 0.71 %
(median = 0.24%) of CD4+ cells. BZLF-1-specific CD8+ T cell responses ranged
from 0. 06% to 3. 55% (median = 1. 97%) of CD8+ cells.
D. Differential kinetics of BZLF- 1-specific CD4+ and CD8+ T cell responses over
the course of AIM.
Consistent with our previous findings , BZLF-1-specific CD4+ T cells were readily
detected at presentation with AIM and declined rapidly thereafter (Table 4.2 and
Figure 1). By contrast , BZLF-1-specific CD8+ T cells , though also detected at
presentation increased in frequency following presentation with AIM
.
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such that peak peptide-specific CD8+ T cell frequencies occurred 3 to 6 wk after
presentation.
Specificity of BZLF- 1-specific C04 and coa+ T cell responses over the
course of AIM.
In addition to the observed differences in the magnitude and kinetics of
BZLF-1-specific CD4+ and CD8+ T cell responses , the regions of the BZLF-
protein targeted by CD4+ and CD8+ T cells within an individual were different
(Table 4. 1 and Figure 4. 1). In most individuals , multiple BZLF-1 peptides were
targeted by both CD4+ and CD8+ T cells (Tables 4. 1 and 4. 2). Consistent with
previous studies (42, 58), overlapping peptide 13 containing the HLA-B8-
restricted RAK epitope was recognized by HLA-B8+ patients , E-1126 and E-1127
during AIM.
F. EBV-specific C04 T cell responses correlate with blood viral load during AIM.
In order to examine the relationship between EBV load and EBV-specific
CD4+ T cell responses , viral load was quantitated over the course of AIM using
real-time PCR (Figure 4.2). We found that EBV load was highest at presentation
with AIM (range: 1. 13 x 10 to 2.28 x 10 copies/10 B cells; median: 1.47 x 10
copies/10 B cells, n=9). To determine whether EBV load at presentation
correlated with antigen-specific CD4+ T cell frequency, log viral load was plotted
against the frequency of CD4+ T cells specific for BZLF- , BMLF- , EBNA- , and
Figure 4.
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Figure 4. 1: Frequency and specificity of BZLF-1-specific CD4+ and CD8+ T cells
following acute EBV infection. Intracellular IFN-y staining was performed after
stimulation with each of the 16 overlapping peptides of BZLF- (peptide
sequences are listed in Table 4. 1). Frequencies of CD69+ IFN- + cells were
calculated after gating on either CD4+ or CD8+ T cell populations. The solid
horizontal line in each plot represents the level of detection of the assay using
peptides (0. 03% for CD4+ cells , 0.04% for CD8+ cells). Note the different y-axis
scale for CD4+ versus CD8+ cells. Representative data from 2 individuals are
shown.
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Figure EBV viral load and EBV-specific CD4+ T cell responses in 9
individuals over the course of AIM. Viral load was determined by Taqman PCR
of DNA extracted from B cell enriched populations. Antigen-specific CD4+ T cell
frequency was determined as in Figure 3. The solid line in each plot
represents the level of detection of the assay (0.06% of CD4+CD45RO+ cells).
EBNA-3A (Figure 4. 3). While BMLF- 1- EBNA- , and EBNA-3A-specific CD4+ T
cell frequency correlated with EBV load at presentation (R=0.
, 0.45 , and 0.
respectively), a weaker correlation was observed between viral load and BZLF-
specific CD4+ T cell frequency (R=0.34). However, it should be noted that one
patient (E-1122) appeared to be an outlier; upon exclusion of this patient
reanalysis of the data revealed a good correlation between viral load and EBV-
specific CD4+ T cell frequency at presentation with AIM (R=0.
, 0. , 0. , and
59 for BZLF- , BMLF- , EBNA- , and EBNA- , respectively).
Viral load dropped rapidly following presentation with AIM
, with the median
viral load dropping 2 log1o by 3 wk following presentation. EBV-specific CD4+ T
cell responses dropped in parallel with viral load , suggesting that these
responses were antigen-dependent. While the frequencies of BZLF- 1-specific
CD8+ T cells also correlated with blood viral load at presentation with AIM (Figure
4.4), BZLF-1-specific CD8+ T cell frequencies subsequently increased in most
individuals as viral load declined.
G. Discussion
Results presented in this chapter show differences in the magnitude
kinetics , and specificity of CD4+ and CD8+ T cell responses against the lytic
protein , BZLF-1. This result supports our hypothesis that differences would be
observed between CD4+ and CD8+ T cell responses directed against the same
Figure 4.
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Figure 4. 3: Relationship between the frequencies of EBV-specific CD4+ T cell
responses and viral load at presentation with AIM. Antigen-specific CD4+ T cell
frequency was determined as in Figure 3. Viral load was determined by
Taqman PCR of DNA extracted from B cell enriched populations. R values
represent correlation coefficients.
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R = 
o 0. 1 1.
0/0 BZLF- Specific CDB + T Cells
Figure 4: Relationship between the frequencies of BZLF-1-specific CD8+ T cell
responses and viral load at presentation with AIM. Frequencies represent the
sum of the highest frequencies of IFN- producing cells to all nonconsecutive
peptides at presentation. Viral load was determined by Taqman PCR of DNA
extract d from B cell enriched populations. R values represent correlation
coefficients.
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protein. However, these differences could reflect intrinsic differences between
CD4+ and CD8+ T cells and/or differences in their priming.
BZLF-1-specific CD4+ T cell responses tended to peak earlier and at lower
frequencies than BZLF-1-specific CD8+ T cell responses, and were not
persistently detectable in most individuals 6 wk or more following presentation
with AIM. By contrast , BZLF-1-specific CD8+ T cell responses remained high
through 6 wk following presentation. Within an individual
, CD4+ and CD8+ T cell
responses targeted different regions of the BZLF- protein. However, it is
important to note that BZLF-1 was recognized by both CD4+ and CD8+ T cells in
all six individuals studied , suggesting that this protein is very immunogenic.
Additionally, the relationship between viral load and T cell responses was
examined. BZLF- , BMLF- , EBNA- , and EBNA-3A-specific CD4+ T cell
responses as well as BZLF-1-specific CD8+ T cell responses correlated with
blood viral load at presentation with AIM. However
, while BZLF- 1-specific CD8+
T cell responses remained high or increased following presentation
, both EBV-
specific CD4+ T cell responses and viral load decreased immediately thereafter.
This may indicate that CD4+ T cell responses are more dependent on the
presence of viral antigen.
CHAPTER V
DIRECT ENUMERATION AND CHARACTERIZATION OF EBV
EPITOPE-SPECIFIC CD4+ T CELLS
A. Introduction
In the previous chapter, we detected differences between BZLF- 1-specific
CD4+ and CD8+ T cell responses and found that EBV-specific CD4+ T cell
responses correlated with blood viral load. In Chapters III and IV
, we found that
EBV-specific CD4+ T cell responses declined rapidly and , unlike EBV-specific
CD8+ T cell responses , were undetectable by intracellular IFN-y staining by 3 wk
to 6 mo following presentation with AIM. However, we hypothesized that
intracellular IFN-y secretion assays may underestimate EBV-specific CD4+ T cell
frequencies. Therefore HLA class II tetramers are used in this chapter to
examine the frequency and functionality EBV-specific CD4+ T cells over the
course of AIM.
B. Identification of BZLF- 1 epitope-specific CD4+ T cell responses.
From our studies using overlapping peptides spanning the BZLF-1 protein
to detect intracellular IFN-y production by CD4+ T cells from patients during AIM
we identified several BZLF- 1 peptide-specific CD4+ T cell responses. In order to
characterize these responses in greater detail , CD4+ T cell lines specific for two
peptides were generated from cryopreserved PBMC obtained at presentation
with AIM. A BZLF-1 peptide #14-specific CD4+ T cell line was generated from
patient E-1125, and a BZLF- peptide #15-specific CD4 + cell line was
generated from patient E-1126. Both peptide-specific CD4+ T cell lines retained
specificity for their respective peptides (Figure 5. 1). HLA DR typing of both
patients is listed in Table 5.
In order to better define the epitopes recognized within the 25-mer
peptides , truncated peptides were synthesized. Stimulation of the CD4+ T cell
lines with the truncated peptides followed by intracellular IFN-y staining was used
to fine map the epitopes. By this method , it was determined that the peptide #14-
specific CD4+ T cell line generated from patient E- 1125 recognized the peptide
OHYREVAAKSSE (aa 198-210) as well as BZLF-1 peptide #14 (data not
shown). We also mapped the peptide #15-specific CD4+ T cell line generated
from patient E-1126 to NDRLRLLLKOMC (aa 211-222) (data not shown). These
two peptide-specific CD4+ T cell responses will be referred to as OHY-specific
and NDR-specific responses.
C. The QHY-specific CD4+ T cell response is restricted by HLA-DR1.
Upon close examination of the QHY peptide sequence
, it was noted that it
contained a predicted binding motif for HLA-DR1. As patient E-1125 is HLA-
DR1+ (HLA-DRB1*0101), we wanted to test whether this response was , in fact
restricted by HLA-DR1. Therefore , we performed intracellular IFN-y assays using
Figure 5.
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Figure 5. 1: BZLF- 1 peptide-specific CD4+ T cell lines derived from AIM patients.
Intracellular IFN-y staining of whole blood at presentation with AIM or derived T
cell line following stimulation with BZLF-1 peptide #14 for patient E- 1125 (a) or
BZLF- 1 peptide #15 for patient E-1126 (b) or A2-restricted HIV Gag peptide as a
negative control. Peptide-specific cells are expressed as a percent of CD4+ cells
co-expressing CD69+ IFN-
Table 5.
Patient HLA-DRB1 Frequency of CD3+CD4+
QHY tetramer+ cells at
presentation with AIM
1125 0101 , 0407
1126 0701 , 1303
1182 11XX/13XX 11XX/14XX
1183 0101 , 13XX
1184 04XX , 12XX
1185 0101 , 03XX
1187 0103 , 08XX 02%
1188 0101 , 04XX
Table 5.1: HLA-DR typing and QHY tetramer staining of selected AIM patients.
Tetramer staining was performed on fresh , whole blood. t indicates that tetramer
staining of patient E-1125 was performed on cryopreserved PBMC. ND= not
done.
peptide-pulsed HLA class II -matched and -mismatched BLCL as antigen
presenting cells. We also used a HLA-DR blocking antibody to distinguish
between HLA-DR- and -DP- or -DQ-restricted responses. Based on these
experiments , it was determined that the QHY-specific CD4+ T cell line was
indeed restricted by HLA-DR1 (Figure 5.2).
O. QHY-specific C04+ T cells can be directly stained with an HLA-OR1 tetramer.
In order to directly stain QHY-specific CD4+ T cells , we tetramerized an
HLA-DR1 monomer loaded with the QHY peptide that was generously provided
by Dr. Larry Stern. Staining of the QHY-specific CD4+ T cell line with this
tetramer revealed that 63% of the CD4+ T cells in this line stained with tetramer
(Figure 5.3). This frequency was comparable to the frequency of CD4+ T cells
that produced IFN-y in response to the QHY peptide (Figure 5. 1). As a negative
control , the QHY-specific CD4+ T cell line did not stain with an HLA-DR1 tetramer
loaded with the Flu HA306 318 peptide (Figure 5.3). As an additional control , the
NDR-specific CD4+ T cell line did not stain with the QHY tetramer.
E. QHY-specific C04+ T cells are detected at high frequency during AIM.
To determine whether QHY-specific CD4+ T cells were generated by other
HLA DR1+ individuals during AIM , blood was collected at presentation and at 1
, 3 , 4 , and 6 wk thereafter. HLA-DR1+ individuals were identified using low-
resolution HLA typing by DNA PCR using sequence-specific primers. Fresh
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Figure 5.2: HLA restriction analysis of the QHY -specific response. Intracellular
IFN-y staining was performed after incubation of the QHY-specific CD4+ T cell
line with QHY peptide-pulsed , HLA class II-matched or -mismatched BLCL. An
HLA-DR-blocking antibody or isotype control was used to confirm HLA-
restriction. Frequencies of CD4+ cells co-expressing CD69+ IFN- + are shown.
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Figure 5.3: Tetramer staining of the QHY-specific CD4+ T cell line. Frequencies
of tetramer-binding cells are expressed as a percent of CD3+CD4+ cells. Staining
of the QHY-specific CD4+ T cell line with Flu HA tetramer and of the NDR-
specific CD4+ T cell line with QHY tetramer were included as specificity controls.
whole blood was stained with QHY tetramer at each timepoint (Figure 5.4). At
presentation, QHY-specific CD4+ T cells were detected at high frequencies
(about 1-2% of CD4+ T cells) in three HLA-DR1+ individuals studied. QHY-
specific CD4+ T cells declined over time , such that by 6 wk following presentation
they were only detected in 2 of 3 individuals at frequencies between 0. 5% of
CD4+ T cells. Controls were included to confirm specificity of tetramer staining
(Figure 5.4). CD4+ T cells from an HLA-DR1+ individual did not stain with an
HLA-DR1 tetramer loaded with the self-peptide , CLIP. Additionally, CD4+ T cells
from three HLA-DR1- individuals with AIM did not stain with the QHY tetramer.
QHY-specific CD4+ T cells decline over time following AIM despite
persistently high viral load.
Because of the rapid decline in QHY-specific CD4+ T cells following
presentation with AIM , we serially quantified blood EBV load to determine
whether the decline in QHY-specific CD4+ T cells could be attributed to a similar
reduction in viral burden. Surprisingly; we found that EBV load remained high in
all three individuals studied (Figure 5. 5) over 6 wk following presentation with
AIM.
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Figure 5. 4: QHY-specific CD4+ T cells over the course of AIM. Tetramer
staining was performed on fresh , whole blood. Representative QHY tetramer
staining of an HLA-DR1+ AIM patient (E-1183) at presentation is shown. Staining
of patient E-1183 with Clip tetramer and of an HLA-DRr patient (E-1184) with
QHY tetramer were included as specificity controls. The lower right panel shows
the mean frequency of CD3+CD4+ gated QHY-tetramet cells in 3 patients over
the course of AIM. Error bars represent SD of replicate tetramer stains.
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Figure 5: Tetramer staining, IFN-y production , and viral load over the course
of AIM. OHY-tetramer staining (0) and intracellular IFN-y staining in response to
OHY peptide stimulation (1') were performed on fresh , whole blood. Viral load (0)
was determined by LightCycler PCR of DNA extracted from B cell enriched
populations.
G. Frequencies of QHY-specific CD4+ T cells detected by tetramer staining
exceed frequencies detected by IFN-y production.
The frequencies of EBV-specific CD4+ T cells detected by tetramer
staining exceeded the frequencies that we had previously detected using flow
cytometry-based IFN-y secretion assays. Thus , we went on to measure and
compare the frequencies of tetramer-staining cells with IFN-y-secreting cells
(Figure 5. 5). We performed tetramer and intracellular IFN-y staining in parallel
using fresh , whole blood. The frequencies of IFN- producing CD4+ T cells
detected were similar to those originally measured ex vivo and used to define the
OHY epitope. In addition , they are comparable to the frequency reported for
CD4+ T cells specific for an epitope derived from the lytic protein , GP350 (59).
However, the frequency of IFN-y production in response to OHY peptide was
markedly lower than the frequencies of tetramer-staining cells.
We had previously detected EBV-specific IFN-y production only from the
CD45RO+ subset of CD4+ cells (60), but recently IFN-y production by GP350-
specific CD4+ T cells expressing CD45RA has been shown (59). We therefore
co-stained with CD45RA in our intracellular IFN-y assays and found that nearly
all QHY-specific , IFN- producing CD4+ T cells were CD45RA negative (data not
shown). This was noteworthy because a high percent of OHY tetramer+ CD4+ T
cells co-expressed CD45RA (50-70% of tetramer+ cells , see below).
H. Intracellular staining for alternative cytokine production
In order to determine whether OHY-specific CD4+ T cells produce
cytokines other than IFN-y in responses to stimulation with QHY peptide , we
stimulated cryopreserved PBMC and co-stained for IL-
, IL- , IL- , mip- , and
mip-1 p. CD4+ T cells did not reproducibly produce any of these cytokines in
response to stimulation with QHY peptide.
I. Low proliferative potential of QHY-specific C04 + T cells in vitro at presentation
with AIM
Because we detected a high frequency of OHY tetramer+ cells that did not
appear to secrete IFN-y, we wanted to further examine their ability to proliferate
using peptide-induced proliferation and CFSE labeling. In preliminary
experiments using cryopreserved PBMC samples from presentation with AIM , we
found that OHY-specific CD4+ T cells did not proliferate well in response 
peptide (Figure 5.6). In fact , the frequency of QHY tetramet cells declined after
incubation with OHY peptide for 5 d. Addition of 10U/ml IL-2 to the culture did
not restore proliferative capacity (data not shown). However, cells from 6 wk
post-presentation appeared to proliferate in response to QHY peptide slightly
better. Interpretation of this data is limited , though , because of low cell number
due to sample availabiliy. Further studies using fresh PBMC are required to
demonstrate a reproducible proliferative defect.
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Figure 5. 6: In vitro proliferative capacity of QHY-specific CD4+ T cells over the
course of AIM. Cryopreserved PBMC from patient E- 1183 at presentation (visit
1) or 6 wk thereafter (visit 6) were labeled with CFSE and incubated with QHY
peptide for 5 d. CFSE intensity is shown after gating on Tetramer CD3+CD4
cells for days 1 (light gray) and 5 (dark gray) of culture with peptide.
Distribution of phenotypic markers on QHY-specific CD4+ T cells is
heterogeneous and similar to that found on general CD4+ T cell population
In our tetramer staining experiments , we co-stained with a number of
phenotypic markers to gain insight into phenotype , homing properties, and
sensitivity to cell death. These markers included CD45RA and RO isoforms
CD28 , CD27 , CD25 , CD40L, L-selectin , LFA- , and Fas. We found that the
frequency of OHY-specific CD4+ T cells co-expressing most of these markers
resembled the frequency of all CD4+ T cells that expressed the given marker.
Specifically, most CD4+ T cells (including OHY-specific CD4+ T cells) during AIM
were heterogeneous for CD45 isoforms, CD28+, CD27+, CD25-, CD40L-, L-
selectin , LFA- , and up to half expressed Fas. potential difference in
CD45RA expression between OHY-specific CD4+ T cells and the CD4+ T cell
population in general was noted. A higher frequency of OHY-specific CD4+ T
cells co-expressed CD45RA. This difference tended to be greatest at the earliest
timepoints during AIM.
K. QHY-specific CD4+ T cells decline over the year following AIM.
In order to determine whether OHY-specific CD4+ T cells were maintained
long-term after AIM , we tetramer stained cryopreserved PBMC from HLA-DR1+
individuals at timepoints up to 1 yr following presentation with AIM (Figure 5.7).
Tetramer staining of cryopreserved PBMC showed lower frequencies of OHY-
specific CD4+ T cells than had been previously found using fresh , whole blood at
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Figure 5. OHY-specific CD4+ T cells through yr following AIM.
Cryopreserved PBMC from HLA-DR1+ individuals (n=4) up to 1 yr were thawed
and stained with OHY-tetramer. Frequencies of tetramer-binding cells are
expressed as a percent of CD3+CD4+ cells. Time 0 represents presentation with
AIM. .
presentation (-0.2% of CD3+CD4+ cells). This was not surprising, as we found
loss of tetramer staining due to cryopreservation in some fresh vs. frozen
comparison experiments (data not shown). By 3 mo to 1 yr following AIM
frequencies of QHY-specific CD4+ T cells were generally very low 
undetectable.
L. Discussion
In this chapter, we hypothesized that EBV-specific CD4+ T cells could be
more accurately quantified by direct staining with HLA class II tetramers. A CD4+
T cell epitope (QHY) derived from the EBV lytic protein , BZLF- , was identified
and shown to be restricted by HLA-DR1. HLA-DR1 tetrameric reagents loaded
with the QHY peptide specifically stained both QHY-specific CD4+ T cell lines
and QHY-specific CD4+ T cells ex vivo from individuals with AIM. Frequencies of
QHY-specific CD4+ T cells were very high at presentation with AIM , but declined
rapidly over time despite persistently high viral load. The kinetics of this
response is similar to the kinetics of lytic epitope-specific CDS+ T cells detected
by tetramer over the first several weeks following AIM (43). QHY-specific CD4+ T
cells were undetectable in 1 of 3 HLA-DR1+ individuals by 6 wk and 2 of 2 HLA-
DR1+ individuals by 1 yr following presentation with AIM.
It is likely that functional assays , such as IFN-y production , underestimate
the frequencies of epitope-specific CD4+ T cells. Early during acute infection
when there is a high viral burden , QHY-specific CD4+ T cells appear to be
stunned" or anergic as determined by lack of IFN- production or low
proliferative potential. While it is possible that in vitro manipulation of highly 
vivo-stimulated T cells may compromise their functional activity (61 , 62), this may
also reflect a potential mechanism by which the virus is able to establish lifelong
persistence.
CHAPTER VI
DISCUSSION
A. Thesis overview
Prior to the current study, little was known about CD4+ T cell responses
during acute EBV infection. As CD4+ T cells play an important role in virus-
specific immunity, especially in the context of persistent infections , the specificity,
timing, magnitude , and functional properties of EBV-specific CD4+ T cells over
the course of primary EBV infection were investigated. Our hypothesis at
initiation of this study was that EBV-specific CD4+ T cells would be detected
during AIM , with responses targeting primarily lytic cycle proteins at the earliest
time-points studied.
Data presented in Chapter 3 uSing intracellular cytokine staining
experiments revealed that, as expected , EBV-specific CD4+ T cell responses
were generated in all individuals (n=17) during AIM. However, these responses
targeted viral proteins expressed during both the lytic and latent cycle of the virus
life cycle. These data were unexpected and show that the antigen recognition
pattern of CD4+ and CD8+ T cells is different during AIM. While EBV-specific
CD4+ T cells were detected at measurable frequencies (up to 2.7% of
CD4+CD45RO+ cells) early in infection , responses declined rapidly over the first
few weeks following presentation with AIM.
In Chapter 4 , relationships between EBV-specific CD4+ T cell responses
and both EBV-specific CD8+ T cell responses and EBV load over the course of
AIM were examined. We hypothesized that differences would be observed
between CD4+ and CD8+ T cell responses directed against the same EBV
protein. We found that both CD4+ and CD8+ T cell responses specific for BZLF-
were detected; however , the magnitude of CD4+ T cell responses was lower than
CD8+ T cell responses. Additionally, the kinetics of BZLF-1-specific CD4+ and
CD8+ T cell responses differed. EBV-specific CD4+ T cell responses declined in
parallel with EBV load over time following presentation with AIM , suggesting that
these responses may be antigen-dependent.
Finally, in Chapter 5 , BZLF-1 epitope-specific CD4+ T cells were detected
directly ex vivo by HLA class II tetramers from HLA-DR1+ individuals with AIM.
We hypothesized that intracellular IFN-y secretion assays may underestimate
EBV-specific CD4+ T cell frequencies. Indeed , we found that frequencies of
tetramer-staining cells far exceeded frequencies detected by peptide-induced
IFN-y production. Moreover, tetramer-staining cells did not proliferate well in
response to peptide stimulation in vitro. These apparent functional impairments
may, in part , explain our inability to detect EBV-specific CD4+ T cells at later
time-points by intracellular IFN-y. However, frequencies of tetramer-staining cells
also decrease over time and are not detected in a small number of HLA-DR1+
individuals by 6 mo to 1 yr following AIM. Data from this chapter suggest a
relationship between acute EBV infection and impaired EBV-specific CD4+ T cell
responses.
B. EBV infection as a system for studying human virus-specific T cell responses
Primary EBV infection is an attractive system for studying the generation
and maintenance of virus-specific T cells in humans because acutely infected
individuals can be readily identified at presentation with symptoms of AIM. Using
this system , the frequencies and specificities of EBV antigen-specific CD8+ T cell
responses have been well characterized (42-44); however, less is known
regarding EBV-specific CD4+ T cell responses over the course of infection. 
therefore undertook the present study in order to characterize the kinetics
specificity, and maintenance of EBV-specific CD4+ T cell responses and to
compare these responses with EBV-specific CD8+ T cell responses and blood
viral load. Marked differences in the expansion , specificity, and stability of EBV-
specific CD4+ and CD8+ T cells were observed over time.
The marked lymphocytosis observed during AIM involves an expansion of
both CD4+ and CD8+ T cells (63). It has recently been shown that the expansion
of CD8+ T cells is largely antigen-specific (42 , 43). The recent discovery of an
EBV- induced superantigen suggests that the CD4+ T cell expansion may, in part
be non-specifically driven (64). However, our data document that at least 2.
of circ'ulating effector/memory CD4+ T cells are EBV-specific. Moreover, this
response is broadly specific in most individuals and is directed at both lytic and
latent EBV antigens. This study constitutes the first ex vivo demonstration of the
antigen-specificity of CD4+ T cells during primary EBV infection.
The early detection of EBV-specific CD4+ T cells during acute EBV
infection in this study are consistent with a previous study documenting the early
detection of CMV-specific CD4+ T cells during primary CMV infection in kidney
transplant recipients (40). Frequencies of CMV-'specific CD4 + T cells peaked
very early (median 7 d) after detection of CMV DNA and declined rapidly
thereafter. However, CMV-specific CD4+ T cells are readily detected in the
peripheral blood of convalescent individuals (40 , 53) even though CMV DNA is
not commonly detected in the peripheral blood of healthy CMV carriers (65).
Differences in the biology of these persistent viruses , such as the location and
degree of antigen expression or the availability of antigen for processing and
presentation , may strongly influence the virus-specific memory T cell pool.
Our findings bear some similarities but important differences from the
results of studies of acute viral infections in mice. Murine studies of LCMV
infection have demonstrated three general phases of T cell responses (reviewed
in (66)). During the expansion phase , the clonal expansion of virus-specific CD8+
cells appears to precede and exceed that of virus-specific CD4+ T cells.
Following clearance of LCMV (a non-persistent virus), virus-specific CD8+ T cells
undergo a more pronounced reduction in frequency than virus-specific CD4+ T
cells (cbntraction phase). After the contraction phase , virus-specific CD8+ T cell
frequencies appear to be stable, while virus-specific CD4+ T cell frequencies
decline (67). Our data are similar to the murine LCMV data in that they
demonstrate a less robust expansion of virus-specific CD4+ T cells than CD8+ T
cells , a phenomenon likely related to the slower rate of CD4+ T cell expansion
documented in in vitro and in vivo studies (66). Of interest , however, is that EBV-
specific CD4+ T cell responses appear to be less well maintained than those
generated during non-persistent infection with LCMV.
C. Lytic vs. latent EBV gene recognition
CD4+ T cell recognition of both lytic and latent proteins during acute EBV
infection in Chapter 3 contrasts with the preferential recognition of lytic proteins
by CD8+ T cells (42-44). Latent protein-specific CD8+ T cells are infrequently
detected at presentation with AIM but become detectable after a few weeks.
Some have suggested that the differences in the pattern of responses to EBV
proteins over time are due to differences in the timing of expression of these
proteins. Our data demonstrating the detection of CD4+ T cells specific for both
lytic and latent proteins at presentation with AIM suggest that the predominance
of lytic-specific over latent-specific CD8+ T cells during acute EBV infection
cannot be accounted for simply by differences in antigen expression. These
differences more likely reflect differences in the availability of these proteins to
the appropriate antigen presenting cells or processing pathways for CD4+ and
CD8+ T cells during acute infection.
One model to explain the differences in antigen recognition by CD4+ and
CD8+ T cells is that the antigen presenting cell type for presentation of lytic and
latent EBV proteins is different for CD4+ and CD8+ T cells. For example , latent
proteins would most likely be expressed in B cells , but not in other infected cell
types. Because EBV drives latently infected B cells into germinal center
reactions , CD4+ T cells surrounding these areas may have better access to latent
protein-expressing B cells than CD8+ T cells that do not enter this area. On the
other hand , lytic proteins would likely be taken up by dendritic cells and
presented to both CD4+ and CD8+ T cells. Alternatively, the antigen presenting
cell type may affect the priming of CD4+ and CD8+ T cells. For example , B cell
priming of latent-specific CD8+ T cells may be different than lytic-specific CD8+ T
cell priming by other antigen presenting cells , such as dendritic cells.
Another model for the lytic vs. latent antigen recognition differences is
the amount of these antigens present and/or the ability of these antigens to be
presented on HLA class I and class II molecules. There is likely a higher amount
of lytic proteins than latent proteins present during an acute infection because
lytic, but not latent, cycle proteins are highly expressed. Latent protein
expression is also tightly regulated. Therefore , CD8+ T cell responses targeting
lytic proteins may predominate simply because of their greater abundance on
HLA class I molecules. Additionally, the processing of EBV lytic and latent
proteins may differ in efficiency. An example of this possibility is the EBNA-
protein , which contains a Gly-Ala repeat region that inhibits its proteasomal
processing and subsequent presentation on HLA class I molecules (68).
However, this does not affect presentation of this protein on HLA class 
molecules , demonstrating a divergence in antigen-specific priming of CD4
+ '
and
CD8+ T cells.
A final argument for the observed antigen recognition pattern is that our
whole blood and PBMC assays detect late-stage , circulating EBV-specific T cells
that are in the process of migrating to another site in the body. Therefore
differences in the magnitude and kinetics of Iytic- and latent-specific CD4+ and
CD8+ T cells could reflect different homing and re-circulation properties of these
cells. In MHV-68 infection of mice , the kinetics of detection of both latent-specific
CD8+ T cells and lytic-specific CD4+ and CD8+ T cells were very similar in three
tissues studied: bronchoalveolar. lavage , mediastinal lymph node , and spleen
(69). However, the magnitude of these responses in each tissue was different.
Interestingly, lytic-specific CD8+ T cell responses peaked earlier than latent-
specific responses. This suggests that the kinetic differences between Iytic- and
latent-specific CD8+ T cell responses are similar in mice and humans despite the
incubation period between EBV infection and presentation with symptoms in
humans.
O. EBV-specific C04+ and coa+ T cell responses
By examining both CD4+ and CD8+ T celllFN-y responses against BZLF-
during AIM , we demonstrated differences in the expansion and stability of BZLF-
1-specific CD4+ and CD8+ T cells. Measured frequencies of BZLF-1-specific
CD4+ T cells were highest at presentation but the rate of detection and the
frequencies of detectable BZLF- 1-specific CD4+ T cells declined over the first 
wk of study. EBV-specific CD4+ T cell frequencies generally paralleled peripheral
blood viral load , a finding that is consistent with the greater dependence of CD4
T cell proliferation on antigen exposure in vitro (70 , 71). By contrast , BZLF-
specific CD8+ T cell frequencies continued to increase in most individuals over
the weeks following presentation and remain detectable during convalescence.
While the frequencies of BZLF-1-specific CD8+ T cells correlated with blood viral
load at presentation with AIM, BZLF-1-specific CD8+ T cell frequencies
subsequently increased in most individuals as viral load declined , suggesting that
the expansion and maintenance of the CD8+ T cell population does not require
persistently high levels of antigen (72).
The difference in kinetics of IFN-y responses between CD4+ and CD8+ T
cells against the same protein suggests that either the priming of these cells is
different or that CD4+ and CD8+ T cells are intrinsically different in the kinetics of
their expansion or functional capabilities. Based on their general functions of
regulation (CD4+) and elimination of virus (CD8+) during an immune response , it
is logical that CD8+ T cells would expand to higher frequencies than CD4+ T
cells. The difference in the kinetics of detection of BZLF-1-specific CD4+ and
CD8+T cells could reflect the migration of these cells out of infected tissue.
Alternatively, BZLF-1-specific CD8+ T cells may be very highly activated at early
time-points and therefore be less effective at secreting IFN-y in response to 
vitro stimulation than at later time-points.
It is very interesting that so many peptides within BZLF-1 are recognized
by CD4+ and CD8+ T cells. While the HLA restriction of each peptide-specific
response was not determined , it is possible that some of the responses are
cross-reactive. A potential consequence of the multi peptide-specific BZLF-
responses is an inability of the virus to mutate to escape the host response. In
fact, the EBV genome is very well conserved , with only two different strains.
Moreover , sequence differences between these strains reside in only a few viral
genes , predominantly in EBNA-3. By sequence conservation , EBV may actually
benefit from host responses that eliminate pathogenic EBV outgrowth and drive
EBV persistence in resting memory B cells.
By tetramer staining, we found that the kinetics of CD4+ T cells specific for
the BZLF-1 QHY epitope during AIM are similar to the kinetics of lytic epitope-
specific CD8+ T cells , which are very high in frequency early but are greatly
culled following AIM (42 , 43). Differential maintenance of lytic epitope-specific
CD8+ T cells into long-term memory has been noted (43). Interestingly, QHY-
specific CD4+ T cells are detected in 2 of 3 of our HLA-DR1+ AIM patients by
tetramer staining 6 wk after presentation with AIM. Future studies wil determine
whether QHY-specific memory CD4+ T cells are generated and persist for life
akin to previously defined lytic epitope-specific CD8+ T cells.
While memory CD8+ T cells specific for both lytic and latent epitopes
persist throughout viral latency, we are unable to detect EBV-specific CD4+ T
cells by IFN-y secretion after 6 mo to 1 yr following acute infection. There are
several potential reasons why we are unable to do so. The frequency of memory
EBV-specific CD4+ T cells may be below the limits of detection of intracellular
IFN-yassays. This possibility is supported by several published studies reporting
the detection of EBV-specific CD4+ T cells during EBV latency (47- , 51 , 73),
many of which required the generation of EBV-specific CD4+ T cell lines from
healthy EBV carriers by long- term in vitro culture. Recently, Paludan and
colleagues reported detection of EBNA-1-specific CD4+ T cells in the peripheral
blood of a small number of healthy EBV carriers by intracellular cytokine staining
at frequencies ranging from 0. 24% to 0.66% of CD4+ T cells (74). However, we
have been unable to replicate these findings despite the fact that our EBNA-
construct (aa 363-641), like their EBNA- construct (aa458-641), contains
defined CD4+ T cell epitopes.
As we have shown in Chapter 5 , high frequencies of EBV epitope-specific
CD4+ T cells detected by direct staining with HLA class II tetramers have
impaired IFN-y and proliferative responses. While we do not yet have tetramers
to detect cells specific for other lytic and latent epitopes , it is possible that EBV-
specific memory CD4+ T cells persist but do not secrete IFN-y, and thus are
undetectable in our assays. Frequencies of circulating EBV-specific CD4+ T cells
may also be below the limit of detection using HLA class II tetramers. Currently,
in vitro culture methods may allow for better detection and expansion of this cell
population , but it is important to note that functional responses of CD4+ T cell
lines do not necessarily reflect ex vivo or in vivo effector capabilities.
EBV-specific CD4+ T cells may be sequestered at sites of viral reactivation
and replication such as the tonsil. Preliminary intracellular IFN-y assays using
cells from tonsillar tissue have not supported this hypothesis; however, additional
functional studies and tetramer staining experiments are needed to further
investigate this possibility.
E. Direct ex vivo staining of EBV-specific CD4+ T cells
While HLA class II tetramer staining of CD4+ T cell lines has been
reported (56 , 75), this is among the first studies to show direct ex vivo staining of
human virus-specific CD4+ T cells over the course of an acute infection. High
frequencies (0. 01- 1 % , n=3) of Borrelia-specific CD4+ T cells from synovial fluid
of treatment-resistent Lyme arthritis patients have been reported (76). More
recently, HCV-specific CD4+ T cells were magnetically isolated from patients who
resolved HCV viremia using HLA-DR4 tetramers (77). These cells were very low
in frequency and represented memory HCV-specific CD4+ T cells. Tetramer
staining of influenza-specific CD4+ T cells within 60 days of immunization has
also been recently reported (78). Frequencies of influenza-specific CD4+ T cells
in that' study (ranging from 1 in 30 000 (0. 003%) to 1 in 600 (0. 17%) CD4+ T cells)
were lower than we report here , most likely because of differences between
acute viral infection and vaccination.
Phenotypically, QHY-specific CD4+ T cells were heterogeneous and did
not differ significantly from the general CD4+ T cell population. The exception
was CD45RA , which was more frequently expressed on tetramer-staining cells.
Recently, a phenotypic analysis of CD4+ T cells that produce IFN-y in response to
lytic (GP350) and latent (EBNA-3C) peptides during primary EBV infection was
performed (59). We find , as was reported for GP350-specific CD4+ T cells , that
QHY-specific CD4+ T cells are CD27+ and CD28+. However, GP350-specific
CD4+ T cells , detected by IFN-y staining, were mostly CD45RO+ , with a minority
CD45RA+ (59). We find that a majority of QHY-specific CD4+ T cells detected by
tetramer staining express CD45RA , but QHY-specific, IFN- producing CD4+ T
cells are also nearly exclusively CD45RO+ These differences likely reflect
marker expression differences between directly stained cells and the subset of
cells that produce IFN-y in response to peptide stimulation. Alternatively, the
epitope specificity may influence CD45 isoform expression.
F. EBV-specific CD4+ T cell responses and EBV load
In Chapter 4 , we found that EBV-specific CD4+ T cell responses and EBV
load generally declined in most individuals over time following AIM. This
suggested that CD4+ T cell responses were antigen-dependent. In Chapter 5
OHY-tetramer+ CD4+ T cells in the three HLA-DR1+ AIM patients studied also
declined in frequency over time despite a sustained , high EBV load.
It is important to note that EBV load , quantitated by DNA PCR , may not be
an accurate reflection of viral gene expression. There is evidence to suggest that
expression of EBV lytic proteins declines following AIM. Prang et al. detected
BZLF-1 transcripts and protein in B cells from individuals with AIM; however , the
percent of B cells expressing lytic proteins decreased after the first week of AIM
(79). BZLF- 1 transcripts, but not protein , were detected in healthy, EBV
seropositive individuals. Therefore , the decline in EBV-specific CD4+ T cells may
reflect a decrease in antigen expression following presentation with AIM.
G. Functional impairment of EBV-specific C04+ T cells during acute infection?
The frequency of IFN-y production in response to OHY peptide was
markedly lower than the frequencies of OHY tetramer-staining cells. Low
frequencies of tetramer positive CD8+ T cells that produce IFN-y in response to
peptide stimulation during AIM have been noted previously (61 , 62). It is
possible that EBV-specific T cells are so highly activated in vivo that some are
incapable of IFN-y production upon restimulation in vitro. However, whereas the
percentage of tetramer-binding CD8+ T cells producing IFN-y in response to
peptide stimulation increased over time following AIM (62), the proportion of
OHY-specific , IFN-y producing CD4+ T cells remained consistently low over time.
A relationship between high viral load and low IFN-y production by CMV-
specific CD4+ T cells has also been reported. In acutely infected children with a
sustained period of viral shedding in urine , lower frequencies of IFN- producing
CMV-specific CD4+ T cells were detected than from acutely infected adults with
no viral shedding in urine (80). In primary CMV infection of transplant recipients
CMV-specific , IFN-y- producing CD4+ T cells were detected much later after virus
detection for symptomatic patients when compared with asymptomatic patients
(38). While there was no statistically significant difference between maximum
viral loads in symptomatic vs. asymptomatic patients, symptomatic patients
tended to have higher viral loads. These. data , along with ours , suggest that
impaired IFN-y responses are a characteristic of high viral burden during acute
infection. It is unclear , however , whether low IFN-y responses of CD4+ T cells
result in , or are a consequence of high viral loads.
We also found that QHY-specific CD4+ T cells did not proliferate well in
response to peptide. Impaired virus-specific CD4+ T cell proliferation during high
viremia and chronic infection has been noted for several human viral infections.
Chronic hepatitis B virus (HBV)- infected individuals have low HBV-specific CD4
T cell proliferative responses , but regain proliferative capacity following treatment
with lamivudine , a potent inhibitor of HBV replication (81). Studies have also
documented an inverse correlation between HIV-1 viremia and HIV-specific CD4+
T cell proliferation (82 , 83). Recently, proliferation of HIV epitope-specific CD4+ T
cells from individuals with high HIV-1 viremia was found to be impaired , but could
be rescued by addition of exogenous IL-2 (84). Our demonstration that QHY-
specific CD4+ T cells from individuals with high EBV loads also show impaired
proliferation suggests that this relationship is common across many chronic viral
infections.
There are several potential mechanisms by which EBV-specific CD4+ T
cells may become irresponsive to stimulation. One possibility is that EBV-
encoded immune modulators may interfere with the priming of EBV-specific
CD4+ T cells. For example , the BCRF-1 protein is a homolog of human IL-
which is an immunosuppressive cytokine. BCRF-1 has been shown to down-
regulate expression of HLA molecules and co-stimulatory molecules on antigen
presenting cells even in the presence of IFN-y (85). Inefficient co-stimulation
may lead to the production of EBV-specific CD4+ T cells that lack effector
function.
Regulatory T cells are also induced in the presence of IL- 10 (86). It is
therefore possible that EBV-specific CD4+ T cells are inhibited by regulatory T
cells. Recently, LMP-1-specific CD4+ T cells from EBV seropositive individuals
were shown to secrete IL-10 and inhibit bystander proliferative and IFN-
responses to mitogen and recall antigen stimulation (87). While BZLF-1-specific
CD4+ T cells may be suppressed by regulatory T cells , we do not believe that
they are regulatory T cells. This is based on our inability to detect IL-
production in response to stimulation and due to their lack of CD25 expression
which is characteristic of regulatory T cells.
H. Conclusion
In conclusion EBV lytic and latent antigen-specific CD4+ T cells are
commonly detected during early EBV infection but differ in their kinetics and
specificity from EBV-specific CD8+ T cell responses. High frequencies of EBV
lytic epitope-specific CD4+ T cells were detected by HLA class II tetramer
staining ex vivo over the course of AIM. Frequencies detected by tetramer
staining exceeded those detected by production of IFN-y in response to peptide
suggesting that functional assays can underestimate the true frequency of
epitope-specific CD4+ T cells.
Early during acute infection , when there is a high viral burden , QHY-
specific CD4+ T cells appear to be "stunned" or anergic as determined by lack of
IFN-y production or low proliferative potential. Whether this is due to the in vitro
manipulation required for our functional assays or reflects a potential mechanism
by which the virus is able to establish lifelong persistence requires further
investigation.
A better understanding of how EBV-specific CD4+ T cells contribute to
resolution of acute infection and/or the establishment of EBV latency has
important implications for prevention and treatment of EBV infection. This thesis
dissertation provides data identifying EBV protein and epitope targets of CD4+ T
cells during acute infection. While , in some cases , the function of EBV epitope-
specific CD4+ T cells may be altered or impaired during natural infection
vaccination and immunotherapeutic strategies aimed at generating strong
responses against these EBV proteins could prove to be effective at preventing
EBV infection and/or treating EBV-associated disease. Additionally, identification
of epitope targets allow for more detailed analyses of the role of CD4+ T cell
responses during infection using reagents such as HLA class II tetramers.
Differences between EBV-specific CD4+ and CD8+ T cell responses may provide
insight into the priming of these cells during acute infection in vivo and suggest
mechanisms by which EBV has evolved to manipulate host responses and avoid
elimination.
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